Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility
Our findings support the use of multimodal ctDNA profiling as a non-invasive approach to identify HRD in prostate cancer. The integration of mutation, genomic instability, and fragmentomic features provides a broader functional view of HRD and may enhance patient stratification for targeted therapies.
Authors
- Isaac Lazzeri (ORCID: https://orcid.org/0000-0002-3609-3443)
- Jasmin Blatterer
- Stefan Kühberger (ORCID: https://orcid.org/0000-0002-9063-1732)
- Karl Kashofer (ORCID: https://orcid.org/0000-0002-5803-4014)
- Angelika Terbuch (ORCID: https://orcid.org/0000-0003-2918-1370)
- Thomas Bauernhofer (ORCID: https://orcid.org/0000-0001-9124-4876)
- Jochen B. Geigl (ORCID: https://orcid.org/0000-0001-9160-0682)
- E. Heitzer
- Christine Beichler
- Nina Monsberger
- Tina Moser
- Matthias J. Moser
- Anna Eberhard
- Emil Thomas Bauernhofer
- Hanieh Sadeghi
- Lisa Glawitch
- Georgios Vlachos
Institutions
- Medical University of Graz (AT)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1038/s41416-025-03301-0
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Karl-Franzens-Universität Graz
- Medizinische Universität Graz
- Bundesministerium für Digitalisierung und Wirtschaftsstandort